{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 41,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a hub-and-spoke diagram to connect the company brand to three core pillars: team, portfolio, and financials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/3",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "diagram",
      "text": null,
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d928487d-9f03-482b-8615-83d497197670",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.28,
        "y": 0.46
      },
      "kind": "list",
      "text": "Industry leading portfolio focused on shutting down the RAS/MAPK pathway. Naporafenib pan-RAFi, ERAS-007 ERKi, ERAS-801 CNS-penetrant EGFRi.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18ea1613-d8f1-47d4-a5ad-5da25d709b9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.28,
        "y": 0.72
      },
      "kind": "list",
      "text": "Strong financial position with high quality investor base and industry visibility. $344M in cash, cash equivalents, and marketable securities; cash runway into H1 2026. Fierce Biotech's 2021 'Fierce 15'.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e70b637-cacb-449f-bec8-78ef88bdc451",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.28,
        "y": 0.23
      },
      "kind": "list",
      "text": "Experienced leadership team and SAB with track record of serial successes. Founded by Jonathan Lim, MD & Kevan Shokat, PhD. World class scientific advisory board. Team with deep experience in global clinical trials.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb9e2576-e96b-41ac-a29d-e43f985ea898",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "CNS = central nervous system. Number of patients alive and free of cancer... Unaudited, as of September 30, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d5ae814-1f34-4d6a-88c1-8f4bfe405755",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "title",
      "text": "Vision to one day erase cancer in at least 100,000 patients annually as a leading global oncology company",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24f689ca-ffac-43c3-8543-de6b2c4c74c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Our name is our mission: to erase cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4d6dfcc-e934-44c5-b1e2-49c7da3f81cc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e1b8209c-15bb-4a54-99fc-65facb70d01f",
      "evidence": "list/bullet: Experienced leadership team and SAB with track record of serial successes. Founded by Jonathan Lim, MD & Kevan Shokat, PhD. World class scientific advisory board. Team with deep experience in global clinical",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "895bcb01-3b78-44f6-956b-a0c0324f3a3d",
      "evidence": "Central logo connected to three distinct strategic pillars.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "7c14303c-7cf7-4655-a29d-3b1346ff20bb",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Setup",
      "beatSlug": "setup",
      "evidence": "Introduction to Erasca's vision and pipeline",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "75b8c386-e12c-4807-b0f3-5e69211b24c3",
      "evidence": "The deck highlights the unmet needs and limitations of current treatments",
      "position": 0,
      "objective": "What is the cost of not investing in Erasca's pipeline?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}